Changes to both the GLP-1 agonist and SGLT2 inhibitor PA criteria were made at the last CareOregon P&T committee. The GLP-1 agonist criteria changes remove the requirement for insulin therapy prior to GLP-1 therapy for certain members. Though SGLT2 inhibitors are typically used for diabetes, certain medications in class like Farxiga also have an indication for chronic kidney disease (CKD). The criteria changes for the SGLT2 inhibitors are limited to the CKD indication. Changes are summarized below.
GLP-1 Agonists
SGLT2 Inhibitors
Bottom Line